Premium
Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapy
Author(s) -
TAHA A. S.,
ANGERSON W. J.,
KNILLJONES R. P.,
BLATCHFORD O.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02784.x
Subject(s) - medicine , antithrombotic , aspirin , warfarin , gastroenterology , clopidogrel , odds ratio , gastrointestinal bleeding , peptic , upper gastrointestinal bleeding , surgery , endoscopy , atrial fibrillation , peptic ulcer
Summary Background Little is known about the site and nature of bleeding lesions related to low‐dose aspirin and other antithrombotic agents. Aim To describe the mucosal abnormalities in patients presenting with upper gastrointestinal bleeding while being treated with these drugs. Methods The endoscopic findings and clinical details were analysed in all patients presenting with haematemesis and/or melaena at a single centre during three calendar years. Associations between endoscopic findings and risk factors, including the intake of non‐steroidal anti‐inflammatory drugs, low‐dose aspirin (75 mg daily) and other antithrombotic drugs including warfarin, clopidogrel, and dipyridamole, were assessed by logistic regression analysis. Results In 674 upper gastrointestinal bleeders, we found that the odds ratio for the presence of erosive oesophagitis in aspirin users was 2 (95% CI, 1–3; P = 0.03) and 3 (2–5; P = 0.0003) in patients taking other antithrombotic agents. In 41 patients with oesophagitis and taking these drugs, 36 (88%) had cardiovascular disease and only 4 (10%) had peptic symptoms. Conclusions Erosive oesophagitis is common in patients with upper gastrointestinal bleeding taking low‐dose aspirin or antithrombotic agents, and could potentially be confused with the coexisting heart disease.